Arbutus Biopharma (ABUS) Shares Outstanding (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $196.9 million the latest figure, recorded in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 2.85% year-over-year to $196.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $196.9 million (up 2.85% YoY) and the FY2025 annual result came in at $192.5 million, up 1.35% from the prior year.
• Shares Outstanding (Entity) improved to $196.9 million in Q1 2026 per ABUS's latest filing, from $192.5 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for ABUS reached as high as $196.9 million in Q1 2026 and fell as low as $148.7 million in Q1 2022.
• A 5-year average of $175.9 million and a median of $180.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 54.53% — and 2025, when it climbed 1.33%.
• Year by year, Shares Outstanding (Entity) stood at $157.5 million in 2022, then gained by 7.88% to $169.9 million in 2023, then grew by 11.83% to $190.0 million in 2024, then advanced by 1.35% to $192.5 million in 2025, then rose by 2.29% to $196.9 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $196.9 million, $192.5 million, and $192.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.